News from KaloBios Pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Sep 30, 2013, 08:00 ET KaloBios to Present at Leerink Swann Rare Disease Roundtable

KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that the company will present at the Leerink Swann Rare Disease Roundtable on October 2 at...


Jun 27, 2013, 08:00 ET KaloBios Provides Update on Pipeline of Clinical Programs

KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on the status of its ongoing clinical programs for KB003, KB001-A and...


Jun 17, 2013, 16:00 ET KaloBios Appoints Donald R. Joseph as Chief Legal Officer

 KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of Donald R. Joseph as Chief Legal Officer.  Mr. Joseph...


Apr 17, 2013, 16:00 ET KaloBios' Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"

KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that David Pritchard, President and Chief Executive Officer, will speak at the BIO 2013...


Jan 31, 2013, 11:33 ET KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering

KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) today announced the pricing of its previously announced initial public offering of 8,750,000...


Jan 10, 2013, 16:00 ET KaloBios Initiates Phase 2 Study with KB001-A Humaneered® Monoclonal Antibody in Cystic Fibrosis Patients

KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of...


Jul 22, 2004, 01:00 ET KaloBios In-Licenses Rheumatoid Arthritis Drug From The Ludwig Institute for Cancer Research

PALO ALTO, Calif., July 22 /PRNewswire/ -- KaloBios Pharmaceuticals, a therapeutic antibody company, announced today that it has exclusively...